Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 (CPVT1)

NCT05122975 is registered in ClinicalTrials.gov with RyCarma Therapeutics, Inc. as lead sponsor.

NCT NCT05122975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05122975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 (CPVT1)
Lead sponsor
RyCarma Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 1, 2023
Completion date
April 1, 2024
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

catecholaminergic polymorphic ventricular tachycardia type 1